Creating a mission-driven MedTech company, fully dedicated to empowering the cardiac surgeons of the future.
To company website
overview
Corcym is a leading global independent MedTech platform focused solely on surgical structural heart solutions. In partnership with the management team assembled by Gyrus, the company was successfully carved out and repositioned, showing strong consistent growth since 2021
4 Foundations
Safer, more effective and longer-lasting treatments for patients with structural heart disease
Perceval valve reduces surgery time and improves outcomes for patients
Diverse portfolio of life-saving products sold globally addressing structural heart disease
Support innovation, particularly around high-growth minimally invasive / robotics techniques
Our investment story
- Gyrus developed the thesis for the evolution of cardiac surgery - from open heart surgery, to MICS (minimally invasive cardiac surgery), to robotics - offering durable solutions that complement and outperform interventional solutions in key segments of the population
- Assembled the management team led by Christian Mazzi (Gyrus Operating Partner) to drive the carve-out
- Executed a complex carve-out in six months - rebuilt core functions, separated contracts, defined new processes, and implemented fit-for-purpose IT systems to establish Corcym as a fully independent structural heart platform
- Post carve-out, launched a series of strategic initiatives to unlock Corcym's full potential:
- Re-started the innovation engine by launching new products (Haart, Perceval Plus with Free tissue, RelyOn) and developing new capabilities (pre-op CT planning, virtual training, endoscopic/robotic academy)
- Optimized operations, centralizing global functions, simplifying manufacturing, and investing in automation and AI – appointed a new COO
- Revamped the commercial model, by introducing a new go-to-market strategy focused on priority accounts, improved service levels, and disciplined approach to pricing
Outcome
Today, Corcym is uniquely positioned as a high-quality, independent platform in a structurally growing cardiac surgery market. From flat / declining revenues, the company has returned to double-digit organic growth, outpacing its reference market and capitalizing on renewed global momentum in cardiac surgery
“My journey at Corcym has been incredibly rewarding. Gyrus brought deep MedTech expertise, hands-on support during the complex carve-out, and strategic insight to help us unlock sustainable growth. Their balanced approach – combining operational discipline with partnership – was instrumental in transforming Corcym into a focused, independent leader in structural heart”
-thumbnail.webp)
Christian Mazzi
Corcym CEO